• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Kamada Ltd.

    12/10/25 9:15:01 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KMDA alert in real time by email
    6-K 1 ea0269087-6k_kamada.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    Report of Foreign Private Issuer

    Pursuant to Rule 13a-16 or 15d-16

    of the Securities Exchange Act of 1934

     

    For the Month of December 2025

     

    Commission File Number 001-35948

     

    Kamada Ltd.

    (Translation of registrant’s name into English)

     

    2 Holzman Street
    Science Park, P.O. Box 4081
    Rehovot 7670402
    Israel
    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

     

    Form 20-F ☒           Form 40-F ☐

     

     

     

     

     

    This Form 6-K is being incorporated by reference into the Registrant’s Form S-8 Registration Statements, File Nos. 333-192720, 333-207933, 333-215983, 333-222891, 333-233267 and 333-265866.

     

    1

     

    Other Information

     

    On December 10, 2025, Kamada Ltd. (the “Company”) held its Annual General Meeting of Shareholders at the Company’s offices located at 2 Holzman Street, Weizmann Science Park, Rehovot, Israel (the “Meeting”). At the Meeting, shareholders voted on and approved, by the requisite majority, each of the proposals described in the Company’s Notice and Proxy Statement for the Meeting, which was attached as Exhibit 99.1 to a Report of Foreign Private Issuer on Form 6-K furnished by the Company to the U.S. Securities and Exchange Commission (“SEC”) on October 23, 2025, as amended by the Amended Proxy Statement for the Meeting attached as Exhibit 99.1 to a Report of Foreign Private Issuer on Form 6-K/A furnished by the Company to the SEC on December 2, 2025.

     

    Accordingly, at the Meeting, the shareholders of the Company approved the following proposals:

     

      1. The re-election of each of the Company’s seven directors to serve as members of the Company’s Board of Directors until the Company’s next annual general meeting of shareholders and until their successors are duly elected.

     

      2. The approval of the grant of options to Mr. Amir London, the Company’s Chief Executive Officer.

     

      3. The adoption of an amended and restated Compensation Policy for Executive Officers and Directors.

     

      4. The approval of certain amendments to the Company’s Articles of Association, including to permit indemnification and insurance of directors and officers under the Israeli Securities Law, 1968 and the Israeli Economic Competition Law, 1988.

     

      5. The approval of an amendment to the exemption and indemnification undertaking letter issued by the Company to each of its directors and officers to provide for indemnification and insurance to the fullest extent permitted under the Israeli Securities Law, 1968 and the Israeli Economic Competition Law, 1988.

     

      6. The ratification and approval of the re-appointment of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as the Company's independent registered public accountants for the year ending December 31, 2025, and for such additional period until the Company’s next annual general meeting of shareholders.

     

    The following exhibits are attached:

     

    99.1   Compensation Policy for Office Holders of the Company
         
    99.2   Amended Articles of Association of the Company

     

    2

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: December 10, 2025 KAMADA LTD.
         
      By: /s/ Nir Livneh
        Nir Livneh
        Vice President General Counsel and
    Corporate Secretary

     

     

    3

     

    Get the next $KMDA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KMDA

    DatePrice TargetRatingAnalyst
    3/21/2025$15.00Buy
    The Benchmark Company
    7/3/2024$18.00Buy
    Stifel
    More analyst ratings

    $KMDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    The Benchmark Company initiated coverage on Kamada with a new price target

    The Benchmark Company initiated coverage of Kamada with a rating of Buy and set a new price target of $15.00

    3/21/25 8:11:15 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on Kamada with a new price target

    Stifel initiated coverage of Kamada with a rating of Buy and set a new price target of $18.00

    7/3/24 7:31:15 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KMDA
    SEC Filings

    View All

    SEC Form 6-K filed by Kamada Ltd.

    6-K - KAMADA LTD (0001567529) (Filer)

    12/10/25 9:15:01 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Kamada Ltd.

    6-K - KAMADA LTD (0001567529) (Filer)

    12/8/25 7:00:07 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 6-K/A filed by Kamada Ltd.

    6-K/A - KAMADA LTD (0001567529) (Filer)

    12/2/25 7:38:36 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KMDA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full-Year Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2026

    Based on the Results of a Planned Interim Futility Analysis the Inhaled AAT Trial is Unlikely to Demonstrate a Statistically Significant Benefit in its Primary Endpoint Kamada Continues to Supply GLASSIA®, its AAT-IV Treatment, Marketed Internationally Including in the U.S. and Canada Through a License Agreement with TAKEDAKamada Reiterates its 2025 Full-Year Revenue Guidance of $178 Million-$182 Million and Adjusted EBITDA of $40 Million-$44 Million  Kamada Projects Double-Digit Growth in Revenues and Profitability in 2026; Detailed Guidance to be Provided in January 2026  Company is Focused on Pursuing Business Development Opportunities to Support Continued Long-Term GrowthManagement to Ho

    12/8/25 7:00:00 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth

    Third Quarter Revenues of $47.0 Million, up 13% Year-over-Year, and Adjusted EBITDA of $11.7 Million, up 34% Year-Over YearNine Month Revenue of $135.8 Million, up 11% Year-over-Year; Adjusted EBITDA of $34.2 Million, up 35% Year-over-Year Positive Outlook for Remainder of 2025 Based on the Company's Diverse Product Portfolio Supports Full-Year Revenue Guidance of $178 Million-$182 Million and Adjusted EBITDA of $40 Million-$44 Million Generated $17.9 Million of Cash from Operations During First Nine Months of 2025; as of September 30, 2025, had $72.0 Million of Available CashCompany Continues to Focus on Advancing Business Development Opportunities to Support Continued Long-Term Annual Doub

    11/10/25 7:00:00 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kamada Announces First Patient Enrolled into an Investigator-Initiated Clinical Trial of CYTOGAM® to Prevent Cytomegalovirus in Kidney Transplantation

    REHOVOT, Israel, and HOBOKEN, N.J. , Nov. 04, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that the first patient was enrolled into an investigator-initiated post-marketing clinical trial of CYTOGAM® (Cytomegalovirus Immune Globulin Intravenous [Human]) (CMV-IGIV) to prevent late Cytomegalovirus ("CMV") infection, a common post-transplant infectious complication that remains an unaddressed medical need, despite recent advances in anti-viral drug therapies. The study, titled "Strategic H

    11/4/25 7:00:00 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KMDA
    Leadership Updates

    Live Leadership Updates

    View All

    Kamada Announces Shareholder Approval and Planned Closing of $60 Million Private Placement with FIMI Opportunity Funds

    Funding Strengthens Kamada's Financial Position, Supporting its Growth Plans and the Pursuit of Strategic Business Development OpportunitiesAppointment of Two New Independent Directors to its Board: Professor Benjamin Dekel and Mr. Assaf Itshayek REHOVOT, Israel and HOBOKEN, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced shareholder approval and planned closing of the previously announced $60 million private placement (the "Private Placement") with FIMI Op

    8/30/23 7:00:00 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kamada Announces Chief Financial Officer Chaime Orlev to Remain in Role and Appointment of Nir Livneh as Vice President, General Counsel and Corporate Secretary

    REHOVOT, Israel and HOBOKEN, N.J., May 24, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))) ("Kamada" or the "Company"), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that following the recently announced $60 million private placement with the FIMI Opportunity Funds, which is expected to contribute to accelerating the growth of its existing business and allow the Company to pursue compelling business development opportunities, Chief Financial Officer (CFO), Chaime Orlev, who had previously planned to transition out of h

    5/24/23 7:05:00 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KMDA
    Financials

    Live finance-specific insights

    View All

    Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full-Year Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2026

    Based on the Results of a Planned Interim Futility Analysis the Inhaled AAT Trial is Unlikely to Demonstrate a Statistically Significant Benefit in its Primary Endpoint Kamada Continues to Supply GLASSIA®, its AAT-IV Treatment, Marketed Internationally Including in the U.S. and Canada Through a License Agreement with TAKEDAKamada Reiterates its 2025 Full-Year Revenue Guidance of $178 Million-$182 Million and Adjusted EBITDA of $40 Million-$44 Million  Kamada Projects Double-Digit Growth in Revenues and Profitability in 2026; Detailed Guidance to be Provided in January 2026  Company is Focused on Pursuing Business Development Opportunities to Support Continued Long-Term GrowthManagement to Ho

    12/8/25 7:00:00 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth

    Third Quarter Revenues of $47.0 Million, up 13% Year-over-Year, and Adjusted EBITDA of $11.7 Million, up 34% Year-Over YearNine Month Revenue of $135.8 Million, up 11% Year-over-Year; Adjusted EBITDA of $34.2 Million, up 35% Year-over-Year Positive Outlook for Remainder of 2025 Based on the Company's Diverse Product Portfolio Supports Full-Year Revenue Guidance of $178 Million-$182 Million and Adjusted EBITDA of $40 Million-$44 Million Generated $17.9 Million of Cash from Operations During First Nine Months of 2025; as of September 30, 2025, had $72.0 Million of Available CashCompany Continues to Focus on Advancing Business Development Opportunities to Support Continued Long-Term Annual Doub

    11/10/25 7:00:00 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025

    REHOVOT, Israel and HOBOKEN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the third quarter and nine months ended September 30, 2025, prior to the open of the U.S. financial markets on Monday, November 10, 2025. Kamada management will host an investment community conference call on Monday, November 10, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties

    11/3/25 7:00:00 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KMDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Kamada Ltd.

    SC 13G/A - KAMADA LTD (0001567529) (Subject)

    11/14/24 6:21:51 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Kamada Ltd. (Amendment)

    SC 13G/A - KAMADA LTD (0001567529) (Subject)

    2/14/24 5:04:02 PM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Kamada Ltd. (Amendment)

    SC 13G/A - KAMADA LTD (0001567529) (Subject)

    2/12/24 12:41:57 PM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care